Alethio Therapeutics Secures $90M Series A for Blood Cancer Antibody

By Priya Anand

Alethio Therapeutics, a biotechnology spinout from the University of Oxford, has raised $90 million in a Series A funding round to advance its lead program targeting essential thrombocythemia (ET). The company, rebranded from Alethiomics in October 2025, focuses on developing biologics for myeloproliferative neoplasms.

The funding will support the development of ATX-011, a first-in-class, mutation-agnostic monoclonal antibody designed to treat ET. ATX-011 aims to replace the current standard-of-care, hydroxyurea, which has limitations such as a slow time to platelet control and a risk of skin cancer. ATX-011 has shown promising results in non-human primate models, normalizing platelet counts within days without myelosuppression.

Alethio plans to submit an Investigational New Drug (IND) application for ATX-011 in the first quarter of 2027, with clinical proof-of-concept data anticipated in the first half of 2028. The ET market is valued at approximately $2 billion, with over 140,000 patients in the United States alone.

In conjunction with the ATX-011 announcement, Alethio has appointed Steve R. Coats, PhD, as Chief Development Officer to guide the program towards clinical trials. The UK Health Research Authority has also approved a three-year therapeutic development research project sponsored by Alethio.